Table 2 Selected clinical studies on... | American Society of Hematology

Table 2

Selected clinical studies on treatment options with combination regimens in patients with relapsed/refractory cHL after ASCT

Agent	No. of patients	Median no. of prior therapies (range)	Prior ASCT	Median no. of cycles given (range)	Response, %	PFS	Reference
GVD	91	1 (NR)	36	2-6	ORR, 70	EFS 8.5 mo (prior ASCT group)	44
					CR, 19
					PR, 51
GemOx	24	2 (1-6)	10	4 (1-12)	ORR, 71	14 mo	45
					CR, 38
					PR, 33
GV	8	3 (1-11)	8	2 (2-4)	ORR, 75	NR	46
					CR, 50
					PR, 25
GCD	14	2 (1-8)	4	4 (1-4)	ORR, 86	NR	47
					CR, 50
					PR, 36
ESHAP	22	≥1 (NR)	2	4 (1-6)	ORR, 73	3-y 27%	48
					CR, 40
					PR, 33
GDP	23	1	0	2 (2-3)	ORR, 69	NR	49
					CR, 17
					PR, 52
DHAP	102	1	0	2	ORR, 88	18-mo FFTF 54%	50
					CR, 21
					PR, 67
ICE	13	1 (1-4)	0	2 (2-3)	ORR, 100	30-mo 69%	51
					CR, 31		52
					PR, 69
IGEV	91	1 (1-4)	0	4	ORR, 81	3-y 53%	53
					CR, 54
					PR, 27
ASHAP	56	1	0	2	ORR, 70	4-y EFS	54
					CR, 34	36%
					PR, 36
ChlVPP	100	0 (0-1)	0	6	ORR, 94	3-y	55
					CR, 88	76%	56
					PR, 6		57

Agent	No. of patients	Median no. of prior therapies (range)	Prior ASCT	Median no. of cycles given (range)	Response, %	PFS	Reference
GVD	91	1 (NR)	36	2-6	ORR, 70	EFS 8.5 mo (prior ASCT group)	44
					CR, 19
					PR, 51
GemOx	24	2 (1-6)	10	4 (1-12)	ORR, 71	14 mo	45
					CR, 38
					PR, 33
GV	8	3 (1-11)	8	2 (2-4)	ORR, 75	NR	46
					CR, 50
					PR, 25
GCD	14	2 (1-8)	4	4 (1-4)	ORR, 86	NR	47
					CR, 50
					PR, 36
ESHAP	22	≥1 (NR)	2	4 (1-6)	ORR, 73	3-y 27%	48
					CR, 40
					PR, 33
GDP	23	1	0	2 (2-3)	ORR, 69	NR	49
					CR, 17
					PR, 52
DHAP	102	1	0	2	ORR, 88	18-mo FFTF 54%	50
					CR, 21
					PR, 67
ICE	13	1 (1-4)	0	2 (2-3)	ORR, 100	30-mo 69%	51
					CR, 31		52
					PR, 69
IGEV	91	1 (1-4)	0	4	ORR, 81	3-y 53%	53
					CR, 54
					PR, 27
ASHAP	56	1	0	2	ORR, 70	4-y EFS	54
					CR, 34	36%
					PR, 36
ChlVPP	100	0 (0-1)	0	6	ORR, 94	3-y	55
					CR, 88	76%	56
					PR, 6		57

Other combination regimens with potential activity in cHL include cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH).

ASHAP, doxorubicin, methylprednisolone, cytarabine, cisplatin; ChlVPP, etoposide, methylprednisolone, chlorambucil, vinblastine, procarbazine prednisone; GCD, gemcitabine, carboplatin, dexamethasone; GDP, gemcitabine, dexamethasone, cisplatin; GemOx, gemcitabine, oxaliplatin; GV, gemcitabine, vinorelbine; ICE, ifosfamide, carboplatin, etoposide; IGEV, ifosfamide, gemcitabine, vinorelbine; NR, not reported.

View Large

This Feature Is Available To Subscribers Only